Home » Coronado Plummets After Drug Fails in Crohn’s Trial
Coronado Plummets After Drug Fails in Crohn’s Trial
Massachusetts-based Coronado Bioscience’s stock fell 70 percent after trials failed to show that its drug candidate based on trichuris suis ova sent Crohn’s patients into remission better than a placebo.
Bloomberg
Bloomberg
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May